Durvalumab (Imfinzi)

Abstract

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses durvalumab (50 mg/mL) concentrate for solution for IV infusion, 1,500 mg in combination with chemotherapy every 3 weeks (q.3.w.), followed by 1,500 mg every 4 weeks (q.4.w.) as monotherapy until disease progression or unacceptable toxicity. Indication: In combination with gemcitabine-based chemotherapy, for the treatment of patients with locally advanced or metastatic biliary tract cancer (BTC).